AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Indivior PLC

Report Publication Announcement Feb 1, 2022

4923_rns_2022-02-01_e9301e1d-1a03-465b-af1b-fe43217d049f.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3008A

Indivior PLC

01 February 2022

Indivior to Announce FY 2021 Results and Host a Presentation on February 16th

Slough, UK, and Richmond, VA, February 1, 2022 - Indivior PLC (LON: INDV) today announced that it will release its FY 2021 results on February 16th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Mark Crossley, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation  via live webcast at 13:00 GMT (8:00 a.m. U.S. Eastern) on February 16th.

Access to the Live Webcast Presentation

The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins.

The webcast link is: https://edge.media-server.com/mmc/p/8tao6fad

Participants may access the presentation telephonically:

·    US participants 1-646-741-3167

·    International participants +44 (0) 2071-928338

Please reference confirmation ID 8268632. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. 

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREANAFEAEAEEA

Talk to a Data Expert

Have a question? We'll get back to you promptly.